What is the appropriate third-line treatment for a patient with stage IV (metastatic) castration‑resistant prostate cancer and an ATR (ataxia‑telangiectasia and Rad3‑related) mutation after prior androgen‑deprivation therapy, an androgen‑receptor‑targeted agent, and taxane chemotherapy?

Third-Line Treatment for Stage IV Prostate Cancer with ATR Mutation

For a patient with metastatic castration-resistant prostate cancer (mCRPC) and an ATR mutation who has progressed after ADT, an androgen receptor pathway inhibitor (ARPI), and taxane chemotherapy, cabazitaxel remains the preferred third-line option, as ATR mutations do not currently have validated targeted therapies with proven survival benefit in this setting.

Critical Clarification on ATR vs HRR Mutations

The question specifies an ATR mutation, which is distinct from the more clinically actionable homologous recombination repair (HRR) gene alterations (BRCA1/2, ATM, PALB2, etc.) that guide PARP inhibitor use. Recent data from the PLANETTE study 1 specifically evaluated the ATR inhibitor ceralasertib in ATM-altered cancers and found limited efficacy, with an objective response rate of only 7.1% in advanced solid tumors and 7.7% composite response rate in mCRPC. ATR mutations themselves do not currently qualify patients for PARP inhibitor therapy or other targeted approaches with established survival benefit.

Recommended Treatment Algorithm

Primary Third-Line Options (Post-ADT, Post-ARPI, Post-Docetaxel):

1. Cabazitaxel (Preferred)

• The 2025 ASCO guideline 2 specifically addresses this clinical scenario in their treatment algorithm for patients previously treated with ADT, ARPI, and docetaxel
• Cabazitaxel demonstrated superior outcomes compared to second-line ARPI in the CARD trial, with improved progression-free survival and overall survival (13.6 vs 11.0 months; HR 0.64, P=0.008) 2
• Dosing: 20-25 mg/m² every 3 weeks with growth factor support
• For aggressive variant mCRPC (visceral metastases, low PSA with bulky disease, high LDH), consider cabazitaxel plus carboplatin (AUC 4 mg/mL per min), which showed PFS benefit (HR 0.69) in heavily pretreated patients 2

2. Lu-177-PSMA-617 (If PSMA-Positive)

• Requires PSMA-PET imaging demonstrating ≥1 PSMA-positive lesion with predominantly PSMA-positive disease and no dominant PSMA-negative lesions 3
• The PSMAfore study demonstrated significantly prolonged median radiographic PFS (11.60 vs 5.59 months; HR 0.49) compared to alternate ARPI 2
• This is the preferred option if the patient is PSMA-positive on imaging 2, 3

3. Radium-223 (If Bone-Only, Symptomatic Disease)

• Reserved for patients with symptomatic bone metastases without visceral involvement 3
• Should not be used with visceral metastases
• Requires concurrent use with denosumab or zoledronic acid 3

4. Pembrolizumab (If MSI-H/dMMR)

• Only for the rare subset with microsatellite instability-high or mismatch repair-deficient tumors 2

Why Not PARP Inhibitors?

The 2025 ASCO guideline 2 emphasizes that PARP inhibitors are indicated for BRCA1/2 and select other HRR alterations (PALB2, certain ATM alterations), but ATR mutations are not among the validated biomarkers for PARP inhibitor therapy. The survival benefit with PARP inhibitors is "most significant for patients with BRCA1/2 when compared to non-BRCA1/2 HRR alterations" 2. ATR is not classified as an HRR gene in the actionable sense for current PARP inhibitor indications.

Clinical Considerations

Biomarker Testing Priority:

• Confirm the specific genetic alteration—if this is actually an ATM (not ATR) alteration, treatment considerations change significantly
• Test for PSMA expression via PSMA-PET imaging before selecting third-line therapy 2
• Consider testing for MSI-H/dMMR status if not previously done

Treatment Selection Factors:

• Performance status and fitness: Cabazitaxel requires adequate bone marrow reserve and performance status
• Disease characteristics: Visceral metastases, symptom burden, PSA kinetics
• Prior treatment responses: Duration of response to first-line ARPI and docetaxel
• Patient preferences: Quality of life considerations, treatment burden

Common Pitfalls:

• Do not confuse ATR with ATM or other HRR genes—they have different therapeutic implications
• Sequential ARPI use (third ARPI after progression on two prior ARPIs) typically yields poor response rates and is not recommended 2
• Early biomarker testing is crucial before starting any line of mCRPC therapy to avoid missing opportunities for targeted therapy 2

Evidence Quality Note

The recommendation for cabazitaxel is based on Level 1 evidence from randomized controlled trials 2, while the ATR-specific data from ceralasertib 1 represents phase IIa evidence showing limited activity, confirming that ATR mutations alone do not currently define a targetable population with available therapies.